facebook

How We Treat Ocular Surface Disease Before Considering Enhancement

1 min read

At Blue Fin Vision®, the ocular surface is assessed and optimised before any enhancement decision is made. This is not a precautionary step, it is a clinical requirement. Proceeding to laser vision correction or further intraocular surgery on an eye with active dry eye or ocular surface disease compromises the accuracy of refractive measurements, increases procedural risk and may not resolve the patient’s visual symptoms.

Corneal topography and biometry rely on a stable tear film to produce accurate readings. ¹ An irregular or deficient tear film introduces measurement error that can translate directly into targeting errors at enhancement. Treating the surface first ensures that the prescription being corrected reflects the true optical state of the eye.

Treatment depends on the underlying mechanism. Aqueous deficiency is managed with lubricating drops and, where indicated, punctal occlusion. Meibomian gland dysfunction, the most common cause of evaporative dry eye, is addressed with lid hygiene, warm compress therapy and in-office treatments where available. ² Inflammatory ocular surface disease may require topical ciclosporin or short-course steroids. ³

Once the ocular surface is stable, refractive measurements are repeated. Only when those readings are consistent and reliable is an enhancement decision made.

References

1. Epitropoulos AT, Matossian C, Berdy GJ, Malhotra RP, Potvin R. Effect of tear osmolarity on repeatability of keratometry for cataract surgery planning. Journal of Cataract and Refractive Surgery. 2015;41(8):1672–1677.

2. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocular Surface. 2017;15(3):438–510.

3. Sheppard JD, Donnenfeld ED, Holland EJ, et al. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye and Contact Lens. 2014;40(5):289–296.

Related Topics:

About Blue Fin Vision®

Blue Fin Vision® is a GMC-registered, consultant-led ophthalmology clinic with CQC-regulated facilities across London, Hertfordshire, and Essex. Patient outcomes are independently audited by the National Ophthalmology Database, confirming exceptionally low complication rates.